Part B Insider - 2003 Issue 27
ONCOLOGY DRUGS: Final Rule Cutting Drug Payments Expected by Nov. 1
Subscribe or sign in to view the full article.
Article Overview
This article covers a CMS policy update affecting oncology practices that dispense chemotherapy drugs and provide drug administration services incident to physician services. It explains that CMS reviewed oncology practice expense survey data, discussed the expected impact on payment levels, and addressed how the agency intended to handle budget neutrality concerns in the broader drug payment reform rulemaking. The piece is relevant to oncology billers, coders, practice managers, and reimbursement professionals watching Medicare drug payment policy.
Why This Topic Matters
The CMS decision described here could affect reimbursement for oncology drug administration and related practice expense payment policy, which is important for practices that dispense or administer drugs and for professionals monitoring Medicare fee schedule changes.
What You Will Learn
- How CMS approached oncology practice expense survey data in its drug payment policy update
- What general types of payment changes were being discussed for drug administration services
- Why the rulemaking was significant for oncology practices and reimbursement planning
- What broader Medicare drug payment reform issues were under consideration
Who Should Read This
- Oncology billing staff
- Medical coders
- Practice managers
- Physician reimbursement professionals
- Medicare policy analysts
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com